
DIABETIC PATIENT FOOT COMPLICATIONS





19 to 34% of people with diabetes will suffer from a DFU in their lifetime.⁽¹⁾

Roughly 60% of **DFU** are infected on presentation.(2)






Up to 1/3 of diabetic patients with DFU will have an amputation.(3)

Up to 85% of diabetic foot-related amputations can be prevented with a holistic approach. (4)

PREVENTIVE ACTIONS FOR DIABETIC PATIENTS (6, 7, 8)





RECOMMENDATIONS (6, 7, 8)



STOP SMOKING







WOUND MANAGEMENT AND GOALS (13, 14, 15, 16, 17) ACCORDING TO EACH DFU GRADE (5)



GRADE 0

No open lesion; Patient may have severely deformed foot.

Skin assessment and care to maintain skin integrity

Wound bed cleansing and

bioburden control to promote a

GRADE

GRADE 2

Superficial ulcer involving the full skin thickness but not underlying tissues

Deep ulcer that penetrates

down to the ligaments and

muscles but not to the

wound healing environment Manage exudate and odor

See grade 1 and additionally the following:

- Infection control
- Advanced wound management (consider skin grafting) for healthy granulation tissue

See grades 1-2 and additionally

Consider surgical management



GRADE 3

bones.

Deep ulcer with cellulitis or abscess formation, often with osteomyelitis



GRADE 4 Localized gangrene

See grades 1-3 and additional the following:

- Surgical debridement
- Prevent infection spreading



- Prevent septicemia
- After amputation, stump and skin management to prevent new wounds

B. BRAUN SOLUTIONS

Daily hygiene and hydration

Correct or eliminate any underlying causes of DFU:

- Respect an adequate diet

Prontosan® Wound Irrigation

chronic wounds.

crust present.

Irrigation Solution.

- Prevents infection(11)

- Reduces healing time⁽¹²⁾

Solution (9) is indicated for cleansing

irrigation and moistening of acute and

- Helps to prevent biofilm formation

Moistens encrusted dressings and ban-

Prontosan® Gel X (9) Proper wound

cleansing is essential. The use of Pronto-

san® Wound Gel X provides long-lasting

cleansing and decontamination of the

wound bed between dressing changes.

dages prior to removal to dissolve any

- Achieve optimal diabetic control including glycemic control, management of high blood pressure, hyperlipidemia
- Address physical traumas due to inadequate foot



Linovera® (9) is indicated in the care of fragile and sensitive skin by increasing skin resistance and protecting it in the

Linovera® **Emulsion** is indicated for the prevention and treatment of lower limb ulcers (vascular and diabetic foot).



Askina® Heel (9) is a non adhesive hydrocellular heel dressing. Askina® Heel protects the heel area from shear stresses and reduces pressure from external



Askina® DresSil Border 6x6 (9)

Askina® DresSil Border Lite (9) is is a self adherent foam dressing. With its circular shaped island of foam a thin, soft, discreet and conformable foam dressing for different anatomical and the additional adhesive border, it contours. It is indicated for use on non is specially designed for small, deep wounds, e.g. diabetic foot ulcers. It may be combined with Askina® Calgitrol® Paste.

Askina® Sorb range (9)

to low exuding wounds.

contains sterile primary wound dressings suitable for the management of moderate to heavily exuding wounds, e.g. DFU. When in contact with wound exudate they form a soft moist gel conducive to natural healing.



Askina® DresSil (9) and Askina® **DresSil Border**(9) are highly

absorbent polyurethane foams with perforated silicone wound contact layers. They help to maintain a moist wound environment conducive to natural healing conditions.



Askina® Calgitrol® (9) is a range of dressings with

an ionic silver alginate matrix providing a broad Prontosan® Debridement Pad (9) antimicrobial effectiveness on infected wounds and has been designed to support the wound bed preparation with Prontosan® Wound preventing contamination from external bacteria.



helps to maintain a moist

wound environment conducive to natural healing conditions. It is composed of a polyurethane foam wound surface with high absorption capacity and a polyurethane film outer layer that is both permeable to vapor and resistant to water and bacteria.



Askina® Carbosorb (9) is a conformable, sterile

wound dressing combining two layers: an absorbent layer and an activated charcoal layer for the absorption of bacterial malodor.



ORDERING INFORMATION

Linovera® Range	Size		Reference
Linovera®	10ml 30ml		Specific references by
Linovera® Emulsion	50ml 100ml		country
Askina [®] Heel	Size	Pcs/Pack	Reference
	surface = 225 cm2	3 5 10	7240103 7240105 7240110
Prontosan*	Size	Pcs/Pack	Reference
Pod	40 ml	24	
Bottle	350 ml	10	
Bottle	1,000 ml	10	Specific references by
Wound Gel	30 ml	20	country
Wound Gel X	50 g	20	
Wound Gel X	250 g	20	
Prontosan® Debridement Pad		Pcs/Pack	Reference
		3	3908456
		10	3908457
Askina® DresSil Border Lite	Size	Pcs/Pack	Reference
	5,5 x 12	10	5385210
	10 x 10	10	5381010
	10 x 20	10	5381210
Askina® DresSil Border	Size overall dressing	Pcs/Pack	Reference
Askina Bressii Boraci	foam island	r cs/r uck	Hererenee
	6 x 6 cm 3 cm Ø	10	5396610
	7,5 x 7,5 cm 4,5 x 4,5 cm	10	5397510
	10 x 10 cm 7 x 7 cm	10	5391010
	10 x 20 cm 7 x 17 cm	10	5391210
	15 x 15 cm 12 x 12 cm	10	5391510
A 11	15 x 20 cm 12 x 17 cm	10	5395210
Askina® DresSil	Size	Pcs/Pack	Reference
	5 x 7 cm	10	5295710
	10 x 10 cm	10	5291010
	15 x 15 cm	10	5291510
	10 x 20 cm	10	5291210
	20 x 20 cm	5	5292005
Askina® DresSil Heel	Size overall dressing	Pcs/Pack	Reference
	foam island		
	22 x 21,6 cm 18,9 x 18,5 cm	5	5592205
Askina® Foam	Size	Pcs/Pack	Reference
	5 x 7 cm	10	7240710
	10 x 10 cm	10	7241010
	10 x 20 cm	10	7241210
	20 x 20 cm	5	7242005
Askina® Sorb	Size	Pcs/Pack	Reference
Dressing	6 x 6 cm	10 15	21155 21005
	10 x 10 cm 15 x 15 cm	3 10 15 3 10	2107S 2116S 2101S 2108S 2102S
Flat Rope	2,7 x 34 cm	10	2105S
Askina [®] Calgitrol [®] Ag	Size	Pcs/Pack	Reference
/ Similar Cangitarion / i.g	10 x 10 cm	10	6211010
	15 x 15 cm	10	6211510
	20 x 20 cm	10	6212010
Askina® Calgitrol® THIN	Size	Pcs/Pack	Reference
Askina Calgitroi IIIIN	5 x 5 cm	10 10	6205510
	J X J CIII		
	10 v 10 cm	10	6201010
	10 x 10 cm	10 10	6201010 6202110
	10 x 20 cm	10	6202110
	10 x 20 cm 20 x 20 cm	10 10	6202110 6202010
Acking® Colgitagl® Docto	10 x 20 cm 20 x 20 cm 20 x 40 cm	10 10 3	6202110 6202010 6202403
Askina® Calgitrol® Paste	10 x 20 cm 20 x 20 cm 20 x 40 cm Size	10 10 3 Pcs/Pack	6202110 6202010 6202403 Reference
Askina® Calgitrol® Paste	10 x 20 cm 20 x 20 cm 20 x 40 cm Size 15g	10 10 3 Pcs/Pack 5	6202110 6202010 6202403 Reference 6241505
Askina® Calgitrol® Paste	10 x 20 cm 20 x 20 cm 20 x 40 cm Size 15g 15g	10 10 3 Pcs/Pack 5 10	6202110 6202010 6202403 Reference 6241505 6241510
	10 x 20 cm 20 x 20 cm 20 x 40 cm Size 15g 15g 100g	10 10 3 Pcs/Pack 5 10	6202110 6202010 6202403 Reference 6241505 6241510 6241001
Askina [®] Calgitrol [®] Paste Askina [®] Carbosorb	10 x 20 cm 20 x 20 cm 20 x 40 cm Size 15g 15g 100g Size	10 10 3 Pcs/Pack 5 10 1 Pcs/Pack	6202110 6202010 6202403 Reference 6241505 6241510 6241001 Reference
	10 x 20 cm 20 x 20 cm 20 x 40 cm Size 15g 15g 100g Size 10 x 10 cm	10 10 3 Pcs/Pack 5 10 1 Pcs/Pack	6202110 6202010 6202403 Reference 6241505 6241510 6241001 Reference 9025006
	10 x 20 cm 20 x 20 cm 20 x 40 cm Size 15g 15g 100g Size	10 10 3 Pcs/Pack 5 10 1 Pcs/Pack	6202110 6202010 6202403 Reference 6241505 6241510 6241001 Reference



- 2. K Markakis, F. L. Bowling, A. J. M. Boulton. The diabetic foot in 2015: an overview. Diabetes Metab Res Rev 2016; 32(Suppl. 1): 169-178. DOI: 10.1002/
- 3. Kim SY, Kim TH, Choi JY, et al. Predictors for Amputation in Patients with Diabetic Foot Wound. Vasc Specialist Int. 2018;34(4):109-116. doi:10.5758/
- vsi.2018.34.4.109); https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340693/

 4. Armstrong DG, Fisher TK, Lepow B, et al. Pathophysiology and Principles of Management of the Diabetic Foot. In: Fitridge R, Thompson M, editors.

 Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists [Internet]. Adelaide (AU): University of Adelaide Press; 2011. 26. https://www.ncbi. nlm.nih.gov/books/NBK534268/)
- 5. Wagner FW Jr. The diabetic foot. Orthopedics. 1987;10:163–72. 6. International Best Pratice Guidelines: Wound Management in Diabetic foot Ulcers. Wound International, 2013. Available from: www.woundsinternational.
- 7. Wounds UK. Best Pratice Statement: Ankle brachial pressure index (ABPI) in pratice. London: Wounds uk, 2019. Available to download from: www.wounds-
- 8. From Complex to Closure: Diabetic Foot Ulcer Assessment and Management Copyright © 2018 WoundSource & Kestrel Health Information, Inc. All rights reserved. www.woundsource.com/practice-accelerator 9. Cf. Instruction for use
- Smieja M, Hunt DL, Edelman D, Etchells E, Cornuz J, Simel DL. Clinical examination for the detection of protective sensation in the feet of diabetic patients. International Cooperative Group for Clinical Examination Research. J Gen Intern Med. 1999;14(7):418-424.
 Moore M, (2016), 0.1% Polyhexanide-Betaine Solution as an Adjuvant in a Case-Series of Chronic Wounds. Surg Technology International Oct 26;29:85-89.
- 12. Bellingeri A, Falciani F, Traspedini P, et al, (2016), Effect of a wound cleansing solution on wound bed preparation and inflammation in chronic wounds: a
- single-blind RCT. J Wound Care. 25(3):160-168. doi:10.12968/jowc.2016.25.3.160. 13. Blume P, Wu S. Updating the Diabetic Foot Treatment Algorithm: Recommendations on Treatment Using Advanced Medicine and Therapies. Wounds. 2018
- Feb;30(2):29-35.
- 14. Ousey, K., Chadwick, P., Jawień, A., Tariq, G., Nair, H. K. R., Lázaro-Martínez, J. L., ... Webb, R. (2018). Identifying and treating foot ulcers in patients with diabetes: saving feet, legs and lives. Journal of Wound Care, 27(Sup5), S1–S52.

 15. Nagoba BS, Gandhi RC, Wadher BJ, Rao A, Hartalkar AR, Selkar SP. A simple and effective approach for the treatment of diabetic foot ulcers with different Wagner grades. Int Wound J. 2010;7(3):153–158. doi:10.1111/j.1742-481X.2010.00666.x
- 16. Alexiadou K, Doupis J. Management of diabetic foot ulcers. Diabetes Ther. 2012;3(1):4. doi:10.1007/s13300-012-0004-9
- 17. Ashraff, S., Siddiqui, M. A., Santos, D., & Carline, T. (2019). Prediction of stump healing in lower limb amputation: a narrative review. Journal of Wound Care,

ALSO AVAILABLE:



Prevention and Treatment of **Wound Infection**



Skin Care



Exudate Management



Pressure Ulcer Management



Basic Product Range

Distributed by:

B. BRAUN MEDICAL | 26 Rue Armengaud | 92210 Saint-Cloud - France

Tel. 01 41 10 53 00 | Fax 01 41 10 53 99

B. BRAUN MEDICAL | SAS with a share capital of 31 000 000 $\ensuremath{\mathfrak{C}}$ | RCS Nanterre 562050856 www.bbraun.com/wound-management

Manufactured by:


B. Braun Medical AG | Infection Control | Seesatz 17 | 6204 Sempach | Switzerland

B. Braun Hospicare Ltd. | Collooney | Co. Sligo | Ireland

Advanced Medical Solutions Ltd. | Premier Park, 33 Road One | Winsford Industrial Estate | Winsford, Cheshire | CW7 3R, U.K. B. Braun Medical SA | Carretera de Terrassa 121 | 08191 Rubi (Barcelona) | Spain

This document, its contents, including institutional data, information, trademarks and logos mentioned herein are the exclusive property of B. Braun. Any representation and/or reproduction, total or partial, of this document and its contents without the express prior consent of B. Braun, is strictly prohibited and constitutes an infringement of the intellectual property rights of B. Braun. Non-binding documents and photographs. For healthcare professional use only.





DIABETIC FOOT ULCER **MANAGEMENT**